Robert Glanzman
Chief Medical Officer
Management
GeNeuro
Switzerland
Biography
Robert received his doctorate in medicine from Wake Forest University School of Medicine in the US. He completed an internship in internal medicine at New York Medical College, a residency in neurology at the University of Michigan, and a fellowship in diagnostic nuclear medicine at Duke University. Robert spent 7 years as an Associate Clinical Professor, where he had a busy clinical practice, taught residents and acted as principal investigator for clinical studies. Robert has been certified by the American Board of Psychiatry and Neurology since 1994. Robert joined industry in 1999. He spent eight years at Pfizer, where he had been Senior Medical Director and Team Leader of the medical affairs team for ©Rebif; he then worked for Novartis starting in 2007, with medical responsibility for the successful Phase III development in the US of ©Gilenya and the commercial launch of ©Extavia. In 2009, he was recruited by Roche Group as Group Medical Director and was in charge from 2009 to 2012 of the ocrelizumab development team, leading this project from the end of Phase II through initiation of Phase III. In 2012, he joined Purdue Pharmaceuticals as Director of Clinical Research. In 2013, he was hired by Nektar Therapeutics as Vice President, Clinical Development. Robert has been in charge of the medical affairs of the Company since December 2015.
Research Interest
Psychiatry and Neurology
